Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia

Nisar A. Baig, Ronald P. Taylor, Margaret A. Lindorfer, Amy K. Church, Betsy R. LaPlant, Adam M. Pettinger, Tait D. Shanafelt, Grzegorz S Nowakowski, Clive S. Zent

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complementdependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance, which is not well characterized. To better understand mechanisms of resistance, we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL. As previously reported, OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and serum complement levels. We now show that after administration of the first dose of OFA, there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substantial ongoing loss of CD20 expression by CLL cells. These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro. Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment. In vitro OFA-mediated CDC did not predict clinical responses, and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo. We propose that optimal efficacy of CD20-targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells.

Original languageEnglish (US)
Pages (from-to)1620-1629
Number of pages10
JournalJournal of Immunology
Volume192
Issue number4
DOIs
StatePublished - Feb 15 2014

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Lymphocyte Count
Therapeutics
Serum
ofatumumab
Complement Activation
Drug Resistance
Immune System
Blood Cells
B-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Baig, N. A., Taylor, R. P., Lindorfer, M. A., Church, A. K., LaPlant, B. R., Pettinger, A. M., ... Zent, C. S. (2014). Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. Journal of Immunology, 192(4), 1620-1629. https://doi.org/10.4049/jimmunol.1302954

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. / Baig, Nisar A.; Taylor, Ronald P.; Lindorfer, Margaret A.; Church, Amy K.; LaPlant, Betsy R.; Pettinger, Adam M.; Shanafelt, Tait D.; Nowakowski, Grzegorz S; Zent, Clive S.

In: Journal of Immunology, Vol. 192, No. 4, 15.02.2014, p. 1620-1629.

Research output: Contribution to journalArticle

Baig, Nisar A. ; Taylor, Ronald P. ; Lindorfer, Margaret A. ; Church, Amy K. ; LaPlant, Betsy R. ; Pettinger, Adam M. ; Shanafelt, Tait D. ; Nowakowski, Grzegorz S ; Zent, Clive S. / Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. In: Journal of Immunology. 2014 ; Vol. 192, No. 4. pp. 1620-1629.
@article{8bdac4ccf1b64e4baaeb1587920d4c4b,
title = "Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia",
abstract = "Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complementdependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance, which is not well characterized. To better understand mechanisms of resistance, we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL. As previously reported, OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and serum complement levels. We now show that after administration of the first dose of OFA, there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substantial ongoing loss of CD20 expression by CLL cells. These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro. Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment. In vitro OFA-mediated CDC did not predict clinical responses, and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo. We propose that optimal efficacy of CD20-targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells.",
author = "Baig, {Nisar A.} and Taylor, {Ronald P.} and Lindorfer, {Margaret A.} and Church, {Amy K.} and LaPlant, {Betsy R.} and Pettinger, {Adam M.} and Shanafelt, {Tait D.} and Nowakowski, {Grzegorz S} and Zent, {Clive S.}",
year = "2014",
month = "2",
day = "15",
doi = "10.4049/jimmunol.1302954",
language = "English (US)",
volume = "192",
pages = "1620--1629",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia

AU - Baig, Nisar A.

AU - Taylor, Ronald P.

AU - Lindorfer, Margaret A.

AU - Church, Amy K.

AU - LaPlant, Betsy R.

AU - Pettinger, Adam M.

AU - Shanafelt, Tait D.

AU - Nowakowski, Grzegorz S

AU - Zent, Clive S.

PY - 2014/2/15

Y1 - 2014/2/15

N2 - Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complementdependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance, which is not well characterized. To better understand mechanisms of resistance, we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL. As previously reported, OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and serum complement levels. We now show that after administration of the first dose of OFA, there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substantial ongoing loss of CD20 expression by CLL cells. These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro. Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment. In vitro OFA-mediated CDC did not predict clinical responses, and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo. We propose that optimal efficacy of CD20-targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells.

AB - Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complementdependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance, which is not well characterized. To better understand mechanisms of resistance, we prospectively studied CLL cells isolated from blood samples collected before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing their first treatment for progressive CLL. As previously reported, OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and serum complement levels. We now show that after administration of the first dose of OFA, there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substantial ongoing loss of CD20 expression by CLL cells. These post-OFA treatment CLL cells were highly resistant to OFA-mediated CDC but retained sensitivity to alemtuzumab-mediated CDC in vitro. Posttherapy serum OFA levels correlated inversely with both the amount of pretreatment circulating cell-bound CD20 and with the decrease in this value following treatment. In vitro OFA-mediated CDC did not predict clinical responses, and the patients with first-dose reactions to OFA did not have markers of increased complement activation in vivo. We propose that optimal efficacy of CD20-targeted therapy for CLL requires determining an mAb dose size and frequency that optimizes CLL killing without exceeding the capacity of the cytotoxic mechanisms and thus minimizes loss of CD20 expression in the surviving CLL cells.

UR - http://www.scopus.com/inward/record.url?scp=84896716648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896716648&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1302954

DO - 10.4049/jimmunol.1302954

M3 - Article

C2 - 24431228

AN - SCOPUS:84896716648

VL - 192

SP - 1620

EP - 1629

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -